GlassScriptPhysician profile
Luis H Camacho
NPI 1336249960
$275,655.00
in general payments reported to CMS, 2019-2025
55 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $33K · 2021: $12K · 2022: $42K · 2023: $31K · 2024: $30K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Travel and Lodging: $14K · Food and Beverage: $5,984 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,140.00 |
| Travel and Lodging | $14,331.62 |
| Food and Beverage | $5,983.89 |
| Education | $279.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $226,960.02 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Amgen INC. | $35,175.03 | 2019-2024 | Mvasi, Lumakras, Kyprolis |
| Exelixis INC. | $3,282.88 | 2019-2025 | Cabometyx |
| Pfizer INC. | $2,447.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $942.79 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Lilly USA, LLC | $680.82 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Medtronic, INC. | $599.34 | 2021-2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $490.24 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Celgene Corporation | $487.00 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Eisai INC. | $409.47 | 2019-2025 | |
| Incyte Corporation | $370.37 | 2020-2025 | Jakafi, Monjuvi, Niktimvo |
| Genentech USA, INC. | $232.49 | 2019-2025 | Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $226.97 | 2019-2024 | |
| Astellas Pharma US INC | $226.11 | 2019-2025 | Xtandi, Padcev |
| Aveo Pharmaceuticals, INC. | $224.44 | 2023-2025 | Fotivda |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.